Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AlloVir, Inc. stock logo
ALVR
AlloVir
$2.91
+4.3%
$6.08
$7.96
$24.15
$14.68M0.6316,394 shs39,619 shs
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
$4.41
$1.35
$50.10
$3.66M1.04227,964 shs650,294 shs
MeiraGTx Holdings plc stock logo
MGTX
MeiraGTx
$5.33
+4.5%
$5.91
$3.85
$8.75
$428.75M1.3362,958 shs99,578 shs
Outlook Therapeutics, Inc. stock logo
OTLK
Outlook Therapeutics
$1.77
+8.7%
$1.46
$0.87
$9.25
$59.21M0.39761,814 shs242,432 shs
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AlloVir, Inc. stock logo
ALVR
AlloVir
+4.30%-12.61%-56.57%-69.40%-83.24%
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
0.00%0.00%0.00%-47.38%-94.96%
MeiraGTx Holdings plc stock logo
MGTX
MeiraGTx
+0.20%-3.77%-25.11%-26.93%-0.78%
Outlook Therapeutics, Inc. stock logo
OTLK
Outlook Therapeutics
+1.24%0.00%+10.14%+18.12%-79.46%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AlloVir, Inc. stock logo
ALVR
AlloVir
N/AN/AN/AN/AN/AN/AN/AN/A
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
MeiraGTx Holdings plc stock logo
MGTX
MeiraGTx
4.4628 of 5 stars
3.52.00.04.82.02.51.9
Outlook Therapeutics, Inc. stock logo
OTLK
Outlook Therapeutics
1.8511 of 5 stars
3.43.00.00.01.90.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AlloVir, Inc. stock logo
ALVR
AlloVir
0.00
N/AN/AN/A
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
3.50
Strong Buy$6.00∞ Upside
MeiraGTx Holdings plc stock logo
MGTX
MeiraGTx
3.00
Buy$24.00350.28% Upside
Outlook Therapeutics, Inc. stock logo
OTLK
Outlook Therapeutics
2.80
Moderate Buy$10.20475.95% Upside

Current Analyst Ratings Breakdown

Latest APTO, ALVR, MGTX, and OTLK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/20/2025
Outlook Therapeutics, Inc. stock logo
OTLK
Outlook Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/14/2025
MeiraGTx Holdings plc stock logo
MGTX
MeiraGTx
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$38.00 ➝ $35.00
3/28/2025
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$2.00 ➝ $6.00
3/17/2025
MeiraGTx Holdings plc stock logo
MGTX
MeiraGTx
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$11.00 ➝ $13.00
(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AlloVir, Inc. stock logo
ALVR
AlloVir
N/AN/AN/AN/A$29.35 per shareN/A
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
N/AN/AN/AN/A($0.19) per shareN/A
MeiraGTx Holdings plc stock logo
MGTX
MeiraGTx
$34.51M12.41N/AN/A$2.17 per share2.46
Outlook Therapeutics, Inc. stock logo
OTLK
Outlook Therapeutics
N/AN/AN/AN/A($1.57) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AlloVir, Inc. stock logo
ALVR
AlloVir
-$190.42M-$20.23N/AN/AN/A-71.03%-61.27%8/7/2025 (Estimated)
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
-$51.21M-$89.19N/AN/AN/AN/A-5,683.22%-300.44%N/A
MeiraGTx Holdings plc stock logo
MGTX
MeiraGTx
-$84.03M-$2.32N/A14.030.37-633.05%-146.38%-53.05%8/11/2025 (Estimated)
Outlook Therapeutics, Inc. stock logo
OTLK
Outlook Therapeutics
-$75.37M-$0.91N/AN/AN/AN/AN/A-225.12%8/13/2025 (Estimated)

Latest APTO, ALVR, MGTX, and OTLK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q2 2025
Outlook Therapeutics, Inc. stock logo
OTLK
Outlook Therapeutics
-$0.55-$0.40+$0.15-$1.50$0.70 millionN/A
5/13/2025Q1 2025
MeiraGTx Holdings plc stock logo
MGTX
MeiraGTx
-$0.38-$0.51-$0.13-$0.51$4.44 million$1.93 million
3/13/2025Q4 2024
MeiraGTx Holdings plc stock logo
MGTX
MeiraGTx
-$0.48-$0.50-$0.02-$0.50$1.50 million$21.39 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AlloVir, Inc. stock logo
ALVR
AlloVir
N/AN/AN/AN/AN/A
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
N/AN/AN/AN/AN/A
MeiraGTx Holdings plc stock logo
MGTX
MeiraGTx
N/AN/AN/AN/AN/A
Outlook Therapeutics, Inc. stock logo
OTLK
Outlook Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AlloVir, Inc. stock logo
ALVR
AlloVir
N/A
86.78
86.78
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
N/A
1.05
1.05
MeiraGTx Holdings plc stock logo
MGTX
MeiraGTx
0.86
2.34
2.34
Outlook Therapeutics, Inc. stock logo
OTLK
Outlook Therapeutics
N/A
0.32
0.64

Institutional Ownership

CompanyInstitutional Ownership
AlloVir, Inc. stock logo
ALVR
AlloVir
66.05%
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
26.62%
MeiraGTx Holdings plc stock logo
MGTX
MeiraGTx
67.48%
Outlook Therapeutics, Inc. stock logo
OTLK
Outlook Therapeutics
11.20%

Insider Ownership

CompanyInsider Ownership
AlloVir, Inc. stock logo
ALVR
AlloVir
32.07%
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
1.33%
MeiraGTx Holdings plc stock logo
MGTX
MeiraGTx
7.50%
Outlook Therapeutics, Inc. stock logo
OTLK
Outlook Therapeutics
4.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
AlloVir, Inc. stock logo
ALVR
AlloVir
1105.04 million3.43 millionOptionable
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
312.14 million63.45 millionNo Data
MeiraGTx Holdings plc stock logo
MGTX
MeiraGTx
30080.37 million71.59 millionOptionable
Outlook Therapeutics, Inc. stock logo
OTLK
Outlook Therapeutics
2033.57 million30.48 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AlloVir stock logo

AlloVir NASDAQ:ALVR

$2.91 +0.12 (+4.30%)
As of 05/27/2025

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.

Aptose Biosciences stock logo

Aptose Biosciences NASDAQ:APTO

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

MeiraGTx stock logo

MeiraGTx NASDAQ:MGTX

$5.33 +0.23 (+4.51%)
As of 11:41 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

Outlook Therapeutics stock logo

Outlook Therapeutics NASDAQ:OTLK

$1.78 +0.15 (+9.33%)
As of 11:42 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.